C-Reactive Protein (CRP) Gene Variants and Coronary Artery Disease in a Chinese Han Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-10-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The recognition of the association between circulating C-reactive protein (CRP) levels and risk of coronary heart disease (CHD) has led to an increased emphasis on CRP genetic effects on CRP level and CHD. However, the causality of CRP variants remains uncertain.The objective of this study is to evaluate the association of CRP gene variants and CRP levels in CHD in Chinese Han population. We conduct case-control study in CRP-Han study participants. The common single-nucleotide polymorphisms (SNPs) in the CRP gene, haplotypes, and plasma CRP levels are detected. A Mendelian randomization analysis will be used to help test the likelihood of causal association of gene-CRP levels, CRP levels-CHD and gene-CHD. The investigators hypothesize that CRP gene variants influence the protein level and may participate in CHD progress.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

CHD patients and non-CHD population are recruited. CRP level and CHD severity by coronary angiograph will be examined. Mendelian randomization analysis are taken to analyze statically.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

CRP coronary artery disease polymorphisms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control

patients without coronary artery disease

No interventions assigned to this group

case

patients with coronary artery disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* clinical diagnosis of coronary artery disease

Exclusion Criteria

* with major organ disfunction or acute inflammatory disease

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Shanghai Institute of Cardiovascular Disease,Zhongshan Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Junbo Ge

Role: STUDY_DIRECTOR

Shanghai Zhongshan Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhongshan Hospital

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chaoneng Wu, PhD

Role: CONTACT

Phone: +86-21-64041990

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Chaoneng Wu

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

30725036

Identifier Type: -

Identifier Source: secondary_id

ZSJQ-30725036